BioNTech and Moderna Face Declining COVID-19 Vaccine Revenue as Cancer Vaccine Development Advances
Source Summary
BioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines. Both companies are shifting focus toward cancer vaccine development as their COVID-19 vaccine sales decline.
Why it matters
The shift from COVID-19 to cancer vaccines represents a strategic pivot for both companies as their primary revenue source diminishes.
